Last reviewed · How we verify
FluMist trivalent (2015-2016)
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened flu virus strains intranasally.
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened flu virus strains intranasally. Used for Influenza prevention in children and adults aged 2-49 years.
At a glance
| Generic name | FluMist trivalent (2015-2016) |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains three live, temperature-sensitive, attenuated influenza virus strains (H1N1, H3N2, and influenza B) that replicate in the cooler upper respiratory tract but cannot replicate in the warmer lower respiratory tract. This triggers both mucosal and systemic immune responses, inducing antibody and cell-mediated immunity against the three circulating influenza strains included in the formulation for that season.
Approved indications
- Influenza prevention in children and adults aged 2-49 years
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
Key clinical trials
- Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years (PHASE3)
- Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (PHASE4)
- Adjuvanted Influenza Vaccine in Stem Cell Transplant (PHASE4)
- Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |